625394-65-2

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
8-Bromo-3,4-dihydro-2H-benzo[1,4]oxazine is used as a key building block for the synthesis of various pharmaceuticals and agrochemicals. Its unique structure allows for the creation of a wide range of compounds with potential therapeutic and pesticidal properties.
Used in Organic Synthesis and Catalysis:
In the field of organic synthesis, 8-Bromo-3,4-dihydro-2H-benzo[1,4]oxazine serves as a valuable ligand, enhancing the efficiency and selectivity of various catalytic processes. Its presence can modulate the reactivity and stability of catalysts, leading to improved synthetic outcomes.
Used in Chemical Research:
8-Bromo-3,4-dihydro-2H-benzo[1,4]oxazine is utilized in chemical research for studying its reactivity in different types of reactions, such as nucleophilic aromatic substitution and Suzuki-Miyaura coupling. Understanding its behavior in these reactions can provide insights into the development of new synthetic methodologies and the design of novel compounds.
Used in Biological and Pharmacological Studies:
8-Bromo-3,4-dihydro-2H-benzo[1,4]oxazine is also used in biological and pharmacological research to explore its potential biological activities and pharmacological properties. This can lead to the discovery of new therapeutic agents or the enhancement of existing ones.

Upstream product

• 625394-74-3 2-(2,6-dibromo-phenoxy)ethylamine 
• 76144-87-1 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl 
• 28165-50-6 2-amino-6-bromophenol 
• 688363-48-6 8-bromo-2H-benzo[b][1,4]oxazin-3(4H)-one 
• 106-93-4 ethylene dibromide 

Downstream Products

• 625394-66-3 8-bromo-3,4-dihydro-2H-benzo[1,4]oxazine, hydrochloride salt 

Relevant academic research and scientific papers

HETEROCYCLE CDK INHIBITORS AND THEIR USE THEREOF

The disclosure is directed to, in part, to heterocycle CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.

PIKFYVE KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.

NOVEL COMPOUNDS

The present invention relates to novel compounds of formula (I) and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin spec

INHIBITORS OF HIF PROLYL HYDROXYLASE

The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.

NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS

Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R3, R4, R4a, R5a, R5b, R5c, R5d, R5e, R6a, R6b, and R6c are defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

Benzoxazine derivatives and uses thereof

The present invention provides a compound of the formula: a pharmaceutically acceptable salt or a prodrug thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9,